Prazosin: A Review of its Pharmacological Properties and Therapeutic Efficacy in Hypertension

Drugs

Volumn 14, Issue 3, 1977, Pages 163-197

  Brogden, R N ^a   Heel, R C ^a   Speight, T M ^a   Avery, G S ^a  

^a Australasian Drug Information Services ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZOXIDE; DIURETIC AGENT; METHYLDOPA; MINIPRES; PHENTOLAMINE; POLYTHIAZIDE; PRAZOSIN; PROPRANOLOL; SODIUM NITRITE; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ALPHA ADRENERGIC RECEPTOR BLOCKING; HEADACHE; HYPERTENSION; KIDNEY FUNCTION; LASSITUDE; NAUSEA; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA RENIN ACTIVITY; REVIEW; SYNCOPE; URINE; VASCULAR RESISTANCE; VERTIGO; XEROSTOMIA;

ANIMAL; BLOOD PRESSURE; CLINICAL TRIALS; COMPARATIVE STUDY; DIURETICS, THIAZIDE; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; HEART RATE; HUMAN; HYDRALAZINE; HYPERTENSION; KIDNEY; KIDNEY DISEASES; KINETICS; METHYLDOPA; PRAZOSIN; QUINAZOLINES; RENIN; TIME FACTORS;

EID: 0017572269     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-197714030-00002     Document Type: Article

References (120)

1. The kidney and antihypertensive therapy
2. Prazosin in the treatment of patients with hypertension and renal function impairment
3. Side-effects due to treatment of hypertension with prazosin
4. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment
5. Clinical evaluation of prazosin as the sole agent for the treatment of hypertension: A double-blind crossover study with methyldopa
6. A preliminary clinical trial of prazosin: a new oral antihypertensive agent
7. Prazosin: preliminary clinical and pharmacological observations
8. Effects of prazosin in patients with hypertension
9. Prazosin, a new quinazoline derivative in the treatment of essential hypertension
10. Comparison of prazosin and methyldopa in mild to moderate hypertension, a multicenter cooperative study
11. Prazosin treatment complicated by acute febrile polyarthritis
12. Prazosin, a selective antagonist of post-synaptic α-adrenoceptors
13. Cardiovascular effects of prazosin in dogs
14. Further studies on cardiovascular effects of prazosin
15. Prazosin hydrochloride (CP-12, 229-1), an oral antihypertensive agent: preliminary clinical observations in ambulatory patients
16. Pharmacokinetics of prazosin, a new antihypertensive compound
17. Analysis of the hypertensive action of prazosin
18. Analysis of the hypotensive action of prazosin
19. Prazosin in patients with chronic renal failure
20. Use of prazosin in management of hypertension in patients with chronic renal failure and renal transplant recipients
21. Prazosin hydrochloride in the treatment of hypertension
22. A new quinazoline derivative in the treatment of hypertension
23. Lack of effect of low doses of prazosin in hypertensive Nigerians
24. Prazosin hydrochloride in the treatment of hypertension
25. Renin characterisation of hypertensive patients treated with vasodilation, beta-blockade and volume depletion
26. Prazosin in the treatment of hypertension
27. Effects of prazosin on blood pressure and plasma renin activity in the anaesthetised dog
28. Differing effects of the vasodilator drugs, prazosin and diazoxide on plasma renin activity in the dog
29. Prazosin: the first-dose phenomenon
30. Alpha blocking action of the antihypertensive agent, prazosin
31. Adverse reactions to prazosin
32. Adverse reactions to prazosin
33. Prazosin: New antihypertensive drug
34. Effect of prazosin on plasma renin activity
35. Experience with prazosin in the treatment of patients with severe hypertension
36. Biochemistry and structure-activity studies with prazosin
37. Studies with prazosin a new effective hypertensive agent
38. Studies with prazosin. A new effective hypotensive agent. II Two double-blind cross-over studies comparing the effects of prazosin and hydrallazine
39. Aendringer i plasma-volume, extracellulaervolumen og den glomerulaere filtrationshastighed under kombinationsbehandling med propranolol og prazosin has patienter med hypertension
40. Adverse drug reactions during treatment of hypertension
41. A study of the use of prazosin in hypertensive patients in Korea
42. Vasodilators in the treatment of hypertension
43. A new look at the treatment of severe hypertension
44. Beta-adrenergic blocking agents in renal failure
45. Physiologic evaluation of a new antihypertensive agent: Prazosin HCl
46. Demonstration of an additive antihypertensive effect of prazosin and polythiazide in out-patients
47. A clinical study on antihypertensive effects of prazosin hydrochloride (‘Minipress’)
48. Hemodynamic changes at rest and during exercise in long term prazosin therapy of essential hypertension
49. Haemodynamic long-term effects of prazosin plus tolamolol in essential hypertension
50. Marshall, A.J.; Barritt, D.W.; Pocock, J. and Heaton, S.T.: Evaluation of beta-blockade, bendrofluazide, and prazosin in severe hypertension: Lancet 1: 271 (1977)
51. Hemodynamic study in men of medium-term treatment with a new amino-quinazoline antihypertensive agent (prazosin)
52. A comparison of the effects of prazosin and hydrallazine on blood pressure, heart rate and plasma renin activity in conscious renal hypertensive dogs
53. Behandling av hypertensjon med prazosin (‘Peripress’) alene og i kombinasjon med beta-blokker: en apen undersokelse hos polikliniske pasienter
54. Prazosin — a double blind evaluation
55. Haemodynamic effects of prazosin
56. Dosage schedule routine for prazosin: two crossover trials comparing t.i.d. with q.i.d. administration and t.i.d. and b.i.d. administration
57. Prazosin in the treatment of hypertension
58. Variability in effect of low doses of prazosin in hypertensive Nigerians
59. Prazosin i behandling av refraktaer hypertensjon
60. A phase II study of prazosin hydrochloride in hypertensive subjects
61. Antihypertensive action of drug combination: polythiazide, prazosin and tolamolol
62. Study on the efficacy and tolerance of a new antihypertensive drug prazosin hydrochloride
63. Prazosin in the treatment of hypertension — a preliminary report
64. The difficult hypertensive
65. Pre-junctional modulation of noradrenergic transmission by noradrenaline, dopamine and acetylcholine
66. Prazosin in treatment of hypertension
67. A cross-over study between hydrallazine and prazosin
68. Prazosin og hydralazin: Ackvipotente antihypertensive doser i Kombinations-behandling med propranolol
69. Adverse reactions to prazosin
70. Prazosin; some clinical observations in ambulatory hypertensive patients
71. Prazosin: severe side-effects are dose dependent
72. Prazosin — a new antihypertensive agent
73. Short-term hemodynamic studies with prazosin
74. Prazosin — a new antihypertensive agent
75. Mechanism of the hypotensive effect of prazosin
76. Treatment of hypertension with the aid of beta-adrenergic blocking drugs
77. Prazosin in treatment of hypertension
78. Prazosin in the treatment of hypertension
79. Prazosin alone and combined with a thiazide diuretic in the treatment of hypertension
80. Influence of dosage and dietary sodium on the first-dose effects of prazosin
81. Prazosin: preliminary report and comparative studies with other antihypertensive agents
82. Multicenter study of the antihypertensive effects of prazosin hydrochloride (prazosin) on mild and moderate hypertension
83. Prescribing prazosin
84. Prazosin in hypertension
85. Clinical experience with prazosin hydrochloride in arterial hypertension
86. A comparative trial of prazosin and mèthyldopa
87. The effect of food intake on the plasma kinetics and toleration of prazosin
88. Double-blind cross-over study comparing prazosin and methyldopa in the treatment of mild hypertension
89. Double-blind crossover comparative study with low doses of prazosin and α-methyldopa
90. Pharmacokinetics of prazosin in man. Presented to the Annual Meeting of the Australasian Society of Clinical and Experimental Pharmacologists, December 1974
91. Prazosin in normal subjects: plasma levels, blood pressure and heart rate
92. Effects of prazosin on sodium and body fluids in genetically hypertensive rats
93. Cardiovascular effects of prazosin in normotensive and genetically hypertensive rats
94. Clinical experience with prazosin in essential blood hypertension therapy (translation)